Cellulite News and Research

RSS

Cellulite describes a condition that is claimed to occur in most women, where the skin of the lower limbs, abdomen, and pelvic region becomes dimpled.

Auxilium initiates XIAFLEX phase IIa trial in Frozen Shoulder syndrome

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first patient has been dosed in its open-label phase IIa trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of idiopathic adhesive capsulitis of the shoulder, also known as Frozen Shoulder syndrome.

1 Dec 2011

BioSpecifics reports $0.3M net income for third quarter 2011 vs. $0.5M net loss for third quarter 2010

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe today announced its financial results for the third quarter ended September 30, 2011 and provided a corporate update. For the quarter, the Company reported net income of $0.3 million or $0.04 per share on a basic and on a fully diluted basis.

9 Nov 2011

Auxilium reports net revenues of $66.7 million for third quarter 2011

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2011.

31 Oct 2011

Dosing commences in Auxilium's XIAFLEX phase IIIb trial for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first patients have been dosed in the Company's phase IIIb trial of XIAFLEX® for the treatment of adult Dupuytren's contracture patients with multiple palpable cords.

3 Oct 2011

Halozyme commences HTI-501 clinical trial for cellulite in women

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite).

28 Sep 2011

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that positive data from a retrospective commercial patient chart review of XIAFLEX (collagenase clostridium histolyticum) used for the treatment of adult Dupuytren's contracture patients with a palpable cord are available via e-posters at the American Society for Surgery of the Hand meeting in Las Vegas.

8 Sep 2011

First aesthetic laser device for long-term reduction in appearance of cellulite

Cynosure, Inc., a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, received a medical device licence issued by Health Canada for the Company's Cellulaze Cellulite Laser Workstation for the reduction in the appearance of cellulite.

7 Sep 2011

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords.

7 Sep 2011

New combined treatment method shows tremendous results for acne scars

Dr. Mark Taylor, a board certified dermatologist at the Gateway Aesthetic Institute & Laser Center in Salt Lake City, Utah, has developed a new method for treating acne scars that is showing tremendous results.

10 Aug 2011

Cynosure announces acquisition of HOYA ConBio's aesthetic laser business

Building on its reputation as a global technology leader in laser and light-based aesthetic systems, Cynosure, Inc. today announced that it has acquired the assets of the aesthetic laser business of HOYA ConBio, a wholly owned subsidiary of Japan-based HOYA Corporation, for $24.5 million in cash. HOYA ConBio is based in Fremont, California.

28 Jun 2011

Simulated Environment delivers SpaCapsule to Elements women's health and fitness center

Simulated Environment Concepts, the manufacturer and developer of medical, aesthetic, weight loss, wellness, and slimming equipment, announced today that the Company has made the first delivery of the SpaCapsule to Elements Diet and Fitness (Elements), a women's health and fitness center, in accordance with the co-branding preferred vendor's agreement executed between the two companies earlier this year.

24 Jun 2011

Cynosure first quarter revenues increase 16% to $21.9 million

Cynosure, Inc. today announced financial results for the three months ended March 31, 2011.

3 May 2011

FDA clears Sound Surgical's new PowerX Lipo System

Sound Surgical Technologies, a leading manufacturer and distributor of body shaping technologies, announced today that the PowerX Lipo System has been cleared for use by the Food and Drug Administration.

26 Apr 2011

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.

11 Mar 2011

Cynosure 2010 fourth quarter revenues increase 16% to $22.3 million

Cynosure, Inc. today announced financial results for the three months and year ended December 31, 2010.

15 Feb 2011

New laser device fights cellulite from under the skin

Over 80% of women today live with the reality of having cellulite, making it one of the biggest cosmetic problems plaguing doctors and patients alike. And while there is everything from quick fixes to extensive invasive procedures to lessen this embarrassing condition, we all wait with anticipation for that modern, miracle treatment that permanently makes our dimpled skin vanish while allowing us to maintain our regular schedules.

10 Feb 2011

Simulated Environment Concepts plans to conduct perception study to provide greater transparency

Simulated Environment Concepts, the manufacturer and developer of medical, aesthetic, weight loss and wellness equipment, announced today the company plans to conduct a perception study as a continued effort to provide greater transparency while maintaining open lines of communication.

29 Jan 2011

Study links large waistline to increased risk of heart problems and type 2 diabetes

Researchers at Eastern Virginia Medical School’s Strelitz Diabetes Center and the school’s department of physiological sciences have published research showing a strong link between a large waistline and increased risk of Type 2 diabetes and cardiovascular disease.

14 Dec 2010

Syneron launches CO2RE CO2 resurfacing system in US and Canada

Syneron Medical Ltd., the global leader in the medical aesthetic device marketplace, announced today the US Food and Drug Administration (FDA) and Health Canada clearance and commercial launch of its highly flexible CO2RE CO2 resurfacing system. CO2RE is a versatile fractional CO2 system that offers the unique ability to treat both superficial and deep skin layers simultaneously with precision-control over the intensity, pattern and depth of ablation.

30 Nov 2010

Alliance Data to provide private label credit services to American Laser Centers

Alliance Data Systems Corporation, a leading provider of loyalty and marketing solutions derived from transaction-rich data, today announced it has signed a long-term agreement with American Laser Centers to provide private label credit services designed to drive sales and enhance long-term customer loyalty.

8 Nov 2010